Tarsus Pharmaceuticals, Inc. (TARS) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Tarsus Pharmaceuticals, Inc. on June 12, 2025. The filing details the results of four proposals submitted to shareholders, including director elections, executive compensation votes, and the ratification of the independent auditor. As of the record date (April 14, 2025), the company had 42,007,037 shares of common stock outstanding.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Director Elections: Two Class II directors were elected to serve until the 2028 annual meeting:
- Katherine Goodrich, M.D., MHS: Received 26,837,786 votes for (95.5% of votes cast excluding broker non-votes).
- Bobak Azamian, M.D., Ph.D.: Received 20,770,139 votes for (75.4% of votes cast excluding broker non-votes).
- Executive Compensation (Say-on-Pay): Stockholders approved the compensation of named executive officers on a non-binding basis with 27,132,839 votes for (98.5% of votes cast).
- Frequency of Say-on-Pay: Stockholders approved conducting future advisory votes on executive compensation on an annual (every 1 year) basis with 26,916,300 votes for.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 34,718,262 votes for (99.6% of votes cast).
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. The document is limited to the procedural results of the shareholder vote.
Investor Verification Checklist
- Verify the full composition of the Board of Directors, noting the re-election of Dr. Azamian and Dr. Goodrich alongside continuing directors Dr. Chaudhuri, Dr. Goldberg, Dr. Link, Mr. Morrison, and Ms. Yarno.
- Confirm the appointment of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2025.
- Review the definitive Proxy Statement filed on April 28, 2025, for detailed executive compensation data referenced in the advisory vote.
- Note that 7,285,501 shares were recorded as broker non-votes across multiple proposals, indicating shares held in street name where brokers lacked discretionary voting authority.